T
CPRX

Tidemark’s Catalyst Pharmaceutical CPRX Stock Holding History

Tidemark’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.92K Hold
320
– – ﹤0.01% 488
2025
Q4 		$7.47K Sell
320
-320
-50% -$7.13K ﹤0.01% 459
2025
Q3 		$12.6K Sell
640
-415
-39% -$8.54K ﹤0.01% 426
2025
Q2 		$22.9K Buy
1,055
+808
+327% +$19.1K 0.01% 348
2025
Q1 		$5.99K Buy
+247
New +$5.56K ﹤0.01% 495

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tidemark's CPRX Position: Q1 2026 in Review

Tidemark held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 320 shares worth $7.92K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

Tidemark first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $22.9K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Tidemark held 320 shares of Catalyst Pharmaceutical worth $7.92K as of Q1 2026.
  • Tidemark left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Tidemark's portfolio in Q1 2026, its #488 holding.
  • Tidemark first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Tidemark's Catalyst Pharmaceutical position peaked at $22.9K in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Tidemark's 13F filing for Q1 2026, filed 7 May 2026.